2024
The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy
Sherwani Z, Damast S, Fields E, Shah S, Beriwal S, Horne Z, Parks E, Kidd E, Leung E, Khoja L, Taunk N, Chino J, Huang C, Russo A, Dyer M, Albuquerque K, Hathout L. The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s32. DOI: 10.1016/j.ijrobp.2024.07.044.Peer-Reviewed Original ResearchRecurrence-free survivalExternal beam radiationMismatch repair statusOverall survivalAdjuvant radiotherapyVaginal brachytherapyAssociated with decreased RFSPromoter hypermethylationInferior recurrence-free survivalProportion of locoregional recurrenceTreated with adjuvant radiotherapyDepth of myometrial invasionLympho-vascular space invasionMulti-institutional cohort studyRetrospective multi-institutional cohort studyCervical stromal involvementSite of recurrenceKaplan Meier methodPost-surgical resectionCox proportional hazards modelsMulti-institutional studyDeficient mismatch repairProportional hazards modelImpact OSLocoregional recurrence
2023
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
de M, Wu L, Hirt C, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O, Group F. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leukemia & Lymphoma 2023, 64: 972-980. PMID: 36960680, DOI: 10.1080/10428194.2023.2185091.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaOverall survivalNPM1 mutationsDe novo acute myeloid leukemiaBone Marrow Pathology GroupMulti-institutional cohort studyNovo acute myeloid leukemiaRetrospective multi-institutional cohort studyShorter overall survivalPoor overall survivalFrequent cytogenetic abnormalityCohort studyMyeloid leukemiaPathology groupCytogenetic abnormalitiesComplex karyotypeUnique genetic landscapeMutations of genesGene mutationsSarcomaGenetic landscapeHigher average numberMutationsLeukemia
2022
Racial Disparities in Patients with Stage IIIC Endometrial Cancer
Patrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Donovan E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. Racial Disparities in Patients with Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e273-e274. DOI: 10.1016/j.ijrobp.2022.07.1283.Peer-Reviewed Original ResearchPositive paraaortic lymph nodesNon-black patientsRecurrence-free survivalExternal beam radiation therapyStage IIIC endometrial carcinomaNon-endometrioid histologyGrade 3 tumorsLymphovascular space invasionOverall survivalBlack patientsVaginal cuff brachytherapyEndometrial carcinomaCervical involvementWorse OSHazard ratioPropensity scoreStage IIIC endometrial cancerMulti-institutional cohort studyRetrospective multi-institutional cohort studyCox proportional hazards modelRacial disparitiesParaaortic lymph nodesKaplan-Meier methodProportional hazards modelBeam radiation therapyPreclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clinical Cancer Research 2022, 29: 174-182. PMID: 36074155, PMCID: PMC9811155, DOI: 10.1158/1078-0432.ccr-22-1138.Peer-Reviewed Original ResearchConceptsBreast cancer brain metastasesActive brain metastasesObjective response rateCNS objective response rateCancer brain metastasesBrain metastasesT-DXdPatient-derived xenograftsPDX modelsCohort studyTrastuzumab deruxtecanClinical efficacyClinical trialsHER2-positive breast cancer brain metastasesMetastatic HER2-positive breast cancerResponse rateMulti-institutional cohort studyHER2-positive breast cancerRetrospective multi-institutional cohort studyOrthotopic patient-derived xenograftsRetrospective cohort studyProspective clinical trialsSubset of patientsCentral nervous system activityPivotal clinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply